Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Manancial - Repositório Digital da UFSM |
dARK ID: | ark:/26339/0013000004vf1 |
Texto Completo: | http://repositorio.ufsm.br/handle/1/25978 |
Resumo: | Severe asthma is a complex syndrome and an important global health problem that requires an integrated therapeutic approach. With this in mind, the aim of the present study was to clinically and functionally evaluate adult patients with severe uncontrolled allergic asthma, treated at the pulmonology service of the University Hospital of Santa Maria (HUSM), of the Federal University of Santa Maria (UFSM), by using omalizumab. This is a retrospective, cross-sectional and descriptive study, with data obtained through the analysis of medical records. The sample was obtained from the HUSM/UFSM pulmonology service database. Patients using omalizumab, a humanized anti-IgE monoclonal antibody, indicated in patients with severe uncontrolled allergic asthma, were included in the study, after a systematic review of treatment adherence, correct medication inhalation technique, environmental control and treatment of comorbidities. Clinical, functional, and laboratory data from 13 patients were evaluated at 16, 32, and 54 weeks after starting medication. Such data were correlated with asthma control outcomes, measured by the Asthma Control Test (ACT) and by pulmonary function, analyzing forced expiratory volume in one second (FEV1), measured by spirometry and the number of exacerbations. The average age was 50.6 years (ranging from 31 to 64 years), 12 individuals were female, 1 male, there were no active smokers, and seven were obese. In eight of the subjects, symptoms had already started. ACT averaged 9.4 points at the initial or baseline assessment, increasing to 17 points after 54 weeks, and FEV1 averaged 1.50 liters at initial or baseline assessment and 1.90 liters after 54 weeks. In both cases data showed a significant variation, both from a statistical point of view (p = 0.04 for ACT and p = 0.02 for FEV1) and from a clinical point of view (increase of more than three points in ACT and more than 100 ml on FEV1). It was not possible to assess the number of exacerbations. The study is in agreement with previous findings in the literature regarding the results of the use of omalizumab in patients with severe uncontrolled allergic asthma. |
id |
UFSM_bac2074b2a41d02c3cb759ea22430601 |
---|---|
oai_identifier_str |
oai:repositorio.ufsm.br:1/25978 |
network_acronym_str |
UFSM |
network_name_str |
Manancial - Repositório Digital da UFSM |
repository_id_str |
|
spelling |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabeEvaluation of patients with severe bronchial asthma using omalizumab in the pneumology service of the University Hospital of Santa MariaAsma alérgica graveOmalizumabeImunoglobulina EExacerbaçãoSevere allergic asthmaOmalizumabImmunoglobulin EExacerbationCNPQ::CIENCIAS DA SAUDESevere asthma is a complex syndrome and an important global health problem that requires an integrated therapeutic approach. With this in mind, the aim of the present study was to clinically and functionally evaluate adult patients with severe uncontrolled allergic asthma, treated at the pulmonology service of the University Hospital of Santa Maria (HUSM), of the Federal University of Santa Maria (UFSM), by using omalizumab. This is a retrospective, cross-sectional and descriptive study, with data obtained through the analysis of medical records. The sample was obtained from the HUSM/UFSM pulmonology service database. Patients using omalizumab, a humanized anti-IgE monoclonal antibody, indicated in patients with severe uncontrolled allergic asthma, were included in the study, after a systematic review of treatment adherence, correct medication inhalation technique, environmental control and treatment of comorbidities. Clinical, functional, and laboratory data from 13 patients were evaluated at 16, 32, and 54 weeks after starting medication. Such data were correlated with asthma control outcomes, measured by the Asthma Control Test (ACT) and by pulmonary function, analyzing forced expiratory volume in one second (FEV1), measured by spirometry and the number of exacerbations. The average age was 50.6 years (ranging from 31 to 64 years), 12 individuals were female, 1 male, there were no active smokers, and seven were obese. In eight of the subjects, symptoms had already started. ACT averaged 9.4 points at the initial or baseline assessment, increasing to 17 points after 54 weeks, and FEV1 averaged 1.50 liters at initial or baseline assessment and 1.90 liters after 54 weeks. In both cases data showed a significant variation, both from a statistical point of view (p = 0.04 for ACT and p = 0.02 for FEV1) and from a clinical point of view (increase of more than three points in ACT and more than 100 ml on FEV1). It was not possible to assess the number of exacerbations. The study is in agreement with previous findings in the literature regarding the results of the use of omalizumab in patients with severe uncontrolled allergic asthma.Asma grave é uma síndrome complexa e um importante problema de saúde global que necessita de uma abordagem terapêutica integrada. Tendo isso em vista, o objetivo do presente estudo foi avaliar clínica e funcionalmente os pacientes adultos com asma alérgica grave não controlada, atendidos no serviço de pneumologia do Hospital Universitário de Santa Maria (HUSM), da Universidade Federal de Santa Maria (UFSM), em uso de omalizumabe. Trata-se de um estudo retrospectivo, transversal e descritivo, com dados obtidos por meio da análise dos prontuários médicos. A amostra foi obtida do banco de dados do serviço de pneumologia do HUSM/UFSM. Foram incluídos no estudo os pacientes que utilizavam omalizumabe, um anticorpo monoclonal humanizado anti-IgE, indicado em pacientes com asma alérgica grave não controlada, após revisão sistematizada da aderência ao tratamento, da técnica inalatória correta das medicações, do controle ambiental e do tratamento das comorbidades. Foram avaliados os dados clínicos, funcionais e laboratoriais de 13 pacientes por 16, 32 e 54 semanas após o início da medicação. Tais dados foram correlacionados com os desfechos de controle da asma, medido pelo Asthma Control Test (ACT) e pela função pulmonar, analisando-se o volume expiratório forçado no primeiro segundo (VEF1), medido pela espirometria e pelo número de exacerbações. A idade foi, em média, 50,6 anos (com variação de 31 a 64 anos), 12 indivíduos eram do sexo feminino, 1 do sexo masculino, nenhum era fumante ativo e sete eram obesos. Em oito dos indivíduos, os sintomas haviam iniciado. O ACT foi, em média, 9,4 pontos na avaliação basal ou inicial, aumentando para 17 pontos após 54 semanas, e o VEF1 foi, em média, 1,50 litros na avaliação inicial ou basal e 1,90 litros após 54 semanas. Ambos os dados apresentaram variação significativa, tanto do ponto de vista estatístico (p = 0,04 para o ACT e p = 0,02 para o VEF1), quanto do ponto de vista clínico (aumento de mais de três pontos no ACT e mais de 100 ml no VEF1). Não foi possível avaliar o número de exacerbações. O estudo está de acordo com os achados prévios na literatura sobre os resultados do uso de omalizumabe nos pacientes com asma alérgica grave não controlada.Universidade Federal de Santa MariaBrasilCiências da SaúdeUFSMPrograma de Pós-Graduação em Ciências da SaúdeCentro de Ciências da SaúdeMarchiori, Roseane Cardosohttp://lattes.cnpq.br/4797974118988345Weinmann, Angela Regina MacielHaeffner, Leris Salete BonfantiFagundes, Ariovaldo Leal2022-08-25T16:54:57Z2022-08-25T16:54:57Z2022-07-08info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/25978ark:/26339/0013000004vf1porAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2022-08-25T16:54:57Zoai:repositorio.ufsm.br:1/25978Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2022-08-25T16:54:57Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false |
dc.title.none.fl_str_mv |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe Evaluation of patients with severe bronchial asthma using omalizumab in the pneumology service of the University Hospital of Santa Maria |
title |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe |
spellingShingle |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe Fagundes, Ariovaldo Leal Asma alérgica grave Omalizumabe Imunoglobulina E Exacerbação Severe allergic asthma Omalizumab Immunoglobulin E Exacerbation CNPQ::CIENCIAS DA SAUDE |
title_short |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe |
title_full |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe |
title_fullStr |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe |
title_full_unstemmed |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe |
title_sort |
Avaliação dos pacientes com asma grave do ambulatório de pneumologia do Hospital Universitário de Santa Maria em uso de omalizumabe |
author |
Fagundes, Ariovaldo Leal |
author_facet |
Fagundes, Ariovaldo Leal |
author_role |
author |
dc.contributor.none.fl_str_mv |
Marchiori, Roseane Cardoso http://lattes.cnpq.br/4797974118988345 Weinmann, Angela Regina Maciel Haeffner, Leris Salete Bonfanti |
dc.contributor.author.fl_str_mv |
Fagundes, Ariovaldo Leal |
dc.subject.por.fl_str_mv |
Asma alérgica grave Omalizumabe Imunoglobulina E Exacerbação Severe allergic asthma Omalizumab Immunoglobulin E Exacerbation CNPQ::CIENCIAS DA SAUDE |
topic |
Asma alérgica grave Omalizumabe Imunoglobulina E Exacerbação Severe allergic asthma Omalizumab Immunoglobulin E Exacerbation CNPQ::CIENCIAS DA SAUDE |
description |
Severe asthma is a complex syndrome and an important global health problem that requires an integrated therapeutic approach. With this in mind, the aim of the present study was to clinically and functionally evaluate adult patients with severe uncontrolled allergic asthma, treated at the pulmonology service of the University Hospital of Santa Maria (HUSM), of the Federal University of Santa Maria (UFSM), by using omalizumab. This is a retrospective, cross-sectional and descriptive study, with data obtained through the analysis of medical records. The sample was obtained from the HUSM/UFSM pulmonology service database. Patients using omalizumab, a humanized anti-IgE monoclonal antibody, indicated in patients with severe uncontrolled allergic asthma, were included in the study, after a systematic review of treatment adherence, correct medication inhalation technique, environmental control and treatment of comorbidities. Clinical, functional, and laboratory data from 13 patients were evaluated at 16, 32, and 54 weeks after starting medication. Such data were correlated with asthma control outcomes, measured by the Asthma Control Test (ACT) and by pulmonary function, analyzing forced expiratory volume in one second (FEV1), measured by spirometry and the number of exacerbations. The average age was 50.6 years (ranging from 31 to 64 years), 12 individuals were female, 1 male, there were no active smokers, and seven were obese. In eight of the subjects, symptoms had already started. ACT averaged 9.4 points at the initial or baseline assessment, increasing to 17 points after 54 weeks, and FEV1 averaged 1.50 liters at initial or baseline assessment and 1.90 liters after 54 weeks. In both cases data showed a significant variation, both from a statistical point of view (p = 0.04 for ACT and p = 0.02 for FEV1) and from a clinical point of view (increase of more than three points in ACT and more than 100 ml on FEV1). It was not possible to assess the number of exacerbations. The study is in agreement with previous findings in the literature regarding the results of the use of omalizumab in patients with severe uncontrolled allergic asthma. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-08-25T16:54:57Z 2022-08-25T16:54:57Z 2022-07-08 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/25978 |
dc.identifier.dark.fl_str_mv |
ark:/26339/0013000004vf1 |
url |
http://repositorio.ufsm.br/handle/1/25978 |
identifier_str_mv |
ark:/26339/0013000004vf1 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Brasil Ciências da Saúde UFSM Programa de Pós-Graduação em Ciências da Saúde Centro de Ciências da Saúde |
publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Brasil Ciências da Saúde UFSM Programa de Pós-Graduação em Ciências da Saúde Centro de Ciências da Saúde |
dc.source.none.fl_str_mv |
reponame:Manancial - Repositório Digital da UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
instname_str |
Universidade Federal de Santa Maria (UFSM) |
instacron_str |
UFSM |
institution |
UFSM |
reponame_str |
Manancial - Repositório Digital da UFSM |
collection |
Manancial - Repositório Digital da UFSM |
repository.name.fl_str_mv |
Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM) |
repository.mail.fl_str_mv |
atendimento.sib@ufsm.br||tedebc@gmail.com |
_version_ |
1815172283923169280 |